首页 | 期刊导航 | 学习空间 | 退出

期刊文章列表

  • Lijuan Ma1,Boyi Li2,Jinchen Ma2,Chunyuan Wu3,Nan Li1,4,Kailin Zhou5,Yun Yan2,Mingshuang Li1,Xiaoyan Hu1,Hao Yan1,Qi Wang2,Yanfei Zheng2,Zhisheng Wu1,4(Beijing University of Chinese Medicine,School of Chinese Materia Medica;Beijing University of Chinese Medicine,School of Traditional Chinese Medicine;Shanghai New Asiatic Pharmaceuticals Hanjiang Co.,Ltd.;Engineering Research Center of Ministry of Education for Traditional Chinese Medicine Pharmaceutical and New Drug Development;Beijing University of Chinese Medicine,School of Humanities).Novel discovery of schisandrin A regulating the interplay of autophagy and apoptosis in oligoasthenospermia by targeting SCF/c-kit and TRPV1 via biosensors[J].Acta Pharmaceutica Sinica B,2023,第6期
  • Jialu Wu1,2,Yue Wan3,Zhenxing Wu1,2,Shengyu Zhang3,Dongsheng Cao4,Chang-Yu Hsieh1,Tingjun Hou1(Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University,College of Pharmaceutical Sciences,Zhejiang University;Carbon Silicon AI Technology Co.,Ltd.;Tencent Quantum Laboratory;Xiangya School of Pharmaceutical Sciences,Central South University).MF-SuP-pKa:Multi-fidelity modeling with subgraph pooling mechanism for pKa prediction[J].Acta Pharmaceutica Sinica B,2023,第6期
  • Yaochen Xie1,Qian Zhou2,Qiaojun He1,Xiaoyi Wang,Jincheng Wang1(Center for Drug Safety Evaluation and Research,Zhejiang Province Key Laboratory of Anti-Cancer Drug Research,College of Pharmaceutical Sciences,Zhejiang University;Department of Pharmacy,Hangzhou Medical College;Department of Nephrology,the First Affiliated Hospital of Huzhou Teachers College,the First People’s Hospital of Huzhou).Opportunities and challenges of incretin-based hypoglycemic agents treating type 2 diabetes mellitus from the perspective of physiological disposition[J].Acta Pharmaceutica Sinica B,2023,第6期
  • Wenxin Zhang1,Xiaohui Pan1,Yanjun Xu2,Hongjie Guo1,Mingming Zheng1,Xi Chen1,Honghai Wu1,Fengming Luan3,Qiaojun He1,4,5,Ling Ding1,Bo Yang1,4(Zhejiang Province Key Laboratory of Anti-Cancer Drug Research,Institute of Pharmacology and Toxicology,College of Pharmaceutical Sciences,Zhejiang University;Department of Medical Thoracic Oncology,the Cancer Hospital of University of Chinese Academy of Sciences(Zhejiang Cancer Hospital),Chinese Academy of Sciences;Department of Gastrointestinal Surgery,Second Affiliated Hospital of Zhejiang University,School of Medicine;The Innovation Institute for Artificial Intelligence in Medicine,Zhejiang University;Cancer Center of Zhejiang University).Mevalonate improves anti-PD-1/PD-L1 efficacy by stabilizing CD274 mRNA[J].Acta Pharmaceutica Sinica B,2023,第6期
  • Bingwei Wang1,Yan Ma1,Sheng Li2,Hang Yao2,Mingna Gu1,Ying Liu1,You Xue1,Jianhua Ding2,Chunmei Ma2,Shuo Yang2,Gang Hu1,2(School of Medicine & Holistic Integrative Medicine,Nanjing University of Chinese Medicine;School of Basic Medical Sciences,Nanjing Medical University).GSDMD in peripheral myeloid cells regulates microglial immune training and neuroinflammation in Parkinson’s disease[J].Acta Pharmaceutica Sinica B,2023,第6期
  • Nan Ru1,Wan-Yang Sun1,Hua-Jun Wang1,Yan-Ping Wu1,Xiao-Fei Zheng1,Rong-Rong He1,2(The First Affiliated Hospital/International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education(MOE)/Guangdong Engineering Research Center of Chinese Medicine & Disease Susceptibility/Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research,Jinan University;State Key Laboratory of Quality Research in Chinese Medicine,Macau University of Science and Technology).Commentary:A nearly forgotten class of anti-inflammatory lipid molecules in central nervous system[J].Acta Pharmaceutica Sinica B,2023,第6期
  • Wei He,Alejandro Sosnik,Chenjie Xu(School of Pharmacy;Shanghai Skin Disease Hospital;Laboratory of Pharmaceutical Nanomaterials Science;Department of Biomedical Engineering).Editor Profile:Guest Editor of Special Column on Delivery Nanotechnologies to Modulate the Immune System and Combat Inflammation and Infection[J].Acta Pharmaceutica Sinica B,2023,第6期
  • Wei He1,2,Alejandro Sosnik3,Chenjie Xu4(School of Pharmacy,China Pharmaceutical University;Shanghai Skin Disease Hospital,Tongji University School of Medicine;Laboratory of Pharmaceutical Nanomaterials Science,Department of Materials Science and Engineering,Technion-Israel Institute of Technology;Department of Biomedical Engineering,City University of Hong Kong).Editorial of Special Column on Delivery Nanotechnologies to Modulate the Immune System and Combat Inflammation and Infection[J].Acta Pharmaceutica Sinica B,2023,第6期
  • Yue Chen1,Jianing Song2,Yihang Cui2,Liyun Zhou2(Dongzhimen Hospital,Beijing University of Chinese Medicine;Pharmcube (Beijing) Co.,Ltd.).Five trends of China’s pharmaceutical industry in 2022[J].Acta Pharmaceutica Sinica B,2023,第6期
  • Jiang Wu,Wenfeng Gou,Zhiyun Wang,Huajie Chang,Deguan Li,Wenbin Hou,Changxiao Liu(Department of Pharmaceutical Engineering;Institute of Radiation Medicine;School of Chinese Materia Medica;Research Center for New Drug Evaluation).Author correction to ‘Discovery of the radioprotecting effect of ecliptae herba,its constituents and targeting p53-mediated apoptosis in vitro and in vivo' [Acta Pharm Sin B 13 (2023) 1216-1230)[J].药学学报(英文版),2023,第6期
  • Ruifang Han,Yu Xiao,Qianqian Bai,Chung Hang Jonathan Choi(Department of Biomedical Engineering,the Chinese University of Hong Kong).Self-therapeutic metal-based nanoparticles for treating inflammatory diseases[J].Acta Pharmaceutica Sinica B,2023,第5期
  • Wei Wei,Qingxuan Zeng,Yan Wang,Xixi Guo,Tianyun Fan,Yinghong Li,Hongbin Deng,Liping Zhao,Xintong Zhang,Yonghua Liu,Yulong Shi,Jingyang Zhu,Xican Ma,Yanxiang Wang,Jiandong Jiang,Danqing Song(Institute of Medicinal Biotechnology,Chinese Academy of Medical Sciences and Peking Union Medical College).Discovery and identification of EIF2AK2 as a direct key target of berberine for anti-inflammatory effects[J].Acta Pharmaceutica Sinica B,2023,第5期
  • Chuanfeng Tang1,Qiaona Wang1,Jingyan Shen1,Congying Wang1,Hong Ding1,Shiyu Wen1,Fan Yang1,Ruiqing Jiao1,Xingxin Wu1,Jianmei Li1,Lingdong Kong1,2(State Key Laboratory of Pharmaceutical Biotechnology,School of Life Sciences,Nanjing University;State Key Laboratory of Natural Medicines,China Pharmaceutical University).Neuron stem cell NLRP6 sustains hippocampal neurogenesis to resist stress-induced depression[J].Acta Pharmaceutica Sinica B,2023,第5期
  • Jie Chen,Xiaohong Wei,Qian Zhang,Yuzhuo Wu,Guiyang Xia,Huan Xia,Lingyan Wang,Hongcai Shang,Sheng Lin(Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing,Dongzhimen Hospital,Beijing University of Chinese Medicine).The traditional Chinese medicines treat chronic heart failure and their main bioactive constituents and mechanisms[J].Acta Pharmaceutica Sinica B,2023,第5期
  • Yun Teng,Yixue Huang,Hao Yu,Cenhao Wu,Qi Yan,Yingjie Wang,Ming Yang,Haifeng Xie,Tianyi Wu,Huilin Yang,Jun Zou(Department of Orthopaedic Surgery,the First Affiliated Hospital of Soochow University).Nimbolide targeting SIRT1 mitigates intervertebral disc degeneration by reprogramming cholesterol metabolism and inhibiting inflammatory signaling[J].Acta Pharmaceutica Sinica B,2023,第5期
  • Boya Chen1,Haiying Zhu1,Bo Yang1,2,Ji Cao1,2,3(Institute of Pharmacology and Toxicology,Zhejiang Province Key Laboratory of Anti-Cancer Drug Research,College of Pharmaceutical Sciences,Zhejiang University;The Innovation Institute for Artificial Intelligence in Medicine,Zhejiang University;Cancer Center of Zhejiang University).The dichotomous role of immunoproteasome in cancer:Friend or foe?[J].Acta Pharmaceutica Sinica B,2023,第5期
  • Chuan Hu,Yujun Song,Yiwei Zhang,Siqin He,Xueying Liu,Xiaotong Yang,Tao Gong,Yuan Huang,Huile Gao(Key Laboratory of Drug Targeting and Drug Delivery Systems,West China School of Pharmacy,Sichuan University).Sequential delivery of PD-1/PD-L1 blockade peptide and IDO inhibitor for immunosuppressive microenvironment remodeling via an MMP-2 responsive dual-targeting liposome[J].Acta Pharmaceutica Sinica B,2023,第5期
  • Bin Tu1,2,Yanrong Gao1,2,Xinran An1,3,Huiyuan Wang1,Yongzhuo Huang1,2,4,5,6(State Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences;University of Chinese Academy of Sciences;University of Michigan College of Pharmacy;Zhongshan Institute for Drug Discovery,SIMM,CAS;NMPA Key Laboratory for Quality Research and Evaluation of Pharmaceutical Excipients;Taizhou University,School of Advanced Study,Institute of Natural Medicine and Health Product).Localized delivery of nanomedicine and antibodies for combating COVID-19[J].Acta Pharmaceutica Sinica B,2023,第5期
  • Yunfei Yin1,Mingyue Tan1,Lianhua Han1,Lei Zhang1,Yue Zhang1,Jun Zhang1,Wanqian Pan1,Jiaxiang Bai1,2,3,Tingbo Jiang1,Hongxia Li1(Department of Cardiology,the First Affiliated Hospital of Soochow University;Department of Orthopedics,the First Affiliated Hospital of Soochow University;Department of Orthopedics,the First Affiliated Hospital of USTC,Division of Life Sciences and Medicine,University of Science and Technology of China).The hippo kinases MST1/2 in cardiovascular and metabolic diseases:A promising therapeutic target option for pharmacotherapy[J].Acta Pharmaceutica Sinica B,2023,第5期
  • Yonghyun Choi1,Wooic Son2,3,Youngpin Han2,3,Jayoung Chae1,Chul-Su Yang2,3,Jonghoon Choi1(School of Integrative Engineering,Chung-Ang University;Department of Molecular & Life Science,Hanyang University;Center for Bionano Intelligence Education and Research,Hanyang University).Glycan targeting nanoparticle for photodynamic immunotherapy of melanoma[J].Acta Pharmaceutica Sinica B,2023,第5期
  • Huitong Ruan1,2,Yongfang Li3,Cheng Wang4,Yixu Jiang4,Yulong Han5,6,Yiwei Li5,6,Dandan Zheng1,Jing Ye4,Gang Chen2,Guo-yuan Yang4,Lianfu Deng1,Ming Guo5,Xingcai Zhang6,Yaohui Tang4,Wenguo Cui1(Department of Orthopaedics,Shanghai Key Laboratory for Prevention and Treatment of Bone and Joint Diseases,Shanghai Institute of Traumatology and Orthopaedics,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine;Jiaxing Key Laboratory of Basic Research and Clinical Translation on Orthopedic Biomaterials,Department of Orthopaedics,the Second Affiliated Hospital of Jiaxing University;Department of Rehabilitation Medicine,Ruijin Hospital,School of Medicine,Shanghai Jiao Tong University;Med-X Research Institute and School of Biomedical Engineering,Shanghai Jiao Tong University;School of Engineering,Massachusetts Institute of Technology;School of Engineering and Applied Sciences,Harvard University).Click chemistry extracellular vesicle/peptide/chemokine nanocarriers for treating central nervous system injuries[J].Acta Pharmaceutica Sinica B,2023,第5期
  • Duo Xu1,2,3,Fan Yang2,3,Jiayao Chen1,3,Tianxing Zhu2,3,Fen Wang4,Yitai Xiao2,3,Zibin Liang3,Lei Bi3,Guolong Huang3,Zebo Jiang2,3,Hong Shan1,3,Dan Li2,3(Center for Interventional Medicine,the Fifth Affiliated Hospital,Sun Yat-sen University;Department of Nuclear Medicine,the Fifth Affiliated Hospital,Sun Yat-sen University;Guangdong Provincial Key Laboratory of Biomedical Imaging and Guangdong Provincial Engineering Research Center of Molecular Imaging,the Fifth Affiliated Hospital,Sun Yat-sen University;Department of Pathology,the First Affiliated Hospital,Sun Yat-sen University).Novel STING-targeted PET radiotracer for alert and therapeutic evaluation of acute lung injury[J].Acta Pharmaceutica Sinica B,2023,第5期
  • Fuhua Wu,Shuang Luo,Yongshun Zhang,Yangsen Ou,Hairui Wang,Zhaofei Guo,Chunting He,Shuting Bai,Penghui He,Min Jiang,Xiaoyan Chen,Guangsheng Du,Xun Sun(Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province,Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology,West China School of Pharmacy,Sichuan University).Single-shot AAV-vectored vaccine against SARS-CoV-2 with fast and long-lasting immunity[J].Acta Pharmaceutica Sinica B,2023,第5期
  • Jiang Xu1,2,Shuai Guo1,2,Xianmei Yin1,Mingqian Li3,He Su4,Xuejiao Liao5,Qiushi Li2,Liang Le2,Shiyu Chen1,2,Baosheng Liao4,Haoyu Hu2,Juan Lei2,Yingjie Zhu6,Xiaohui Qiu4,Lu Luo2,Jun Chen,Ruiyang Cheng2,Zhenzhan Chang8,Han Zhang9,Nicholas Chieh Wu10,Yiming Guo11,Dianyun Hou12,Jin Pei1,Jihai Gao1,Yan Hua13,Zhihai Huang4,Shilin Chen1,2(Institute of Herbgenomics,State Key Laboratory of Southwest Chinese Medicine Resources,Pharmacy College,Chengdu University of Traditional Chinese Medicine;Institute of Chinese Materia Medica,China Academy of Chinese Medical Sciences;Key Laboratory of Cancer Prevention and Therapy Combining Traditional Chinese and Western Medicine of Zhejiang Province,Zhejiang Academy of Traditional Chinese Medicine,Tongde Hospital of Zhejiang Province;Guangdong Provincial Hospital of Chinese Medicine(the Second Clinical Medical College of Guangzhou University of Chinese Medicine,Guangdong Provincial Hospital of Traditional Chinese Medicine);Pharmacy College,Shandong University of Traditional Chinese Medicine;Department of Pathology,Memorial Sloan Kettering Cancer Center;Beijing Engineering Research Center of Pediatric Surgery,Engineering and Transformation Center,Beijing Children’s Hospital,National Center for Children’s Health,Capital Medical University;School of Basic Medical Sciences,Peking University;School of Chinese Materia Medica,Tianjin University of Traditional Chinese Medicine;School of Life and Environmental Sciences,the University of Sydney;University of Pittsburgh,Kenneth P.Dietrich School of Arts and Sciences;Agricultural College,Henan University of Science and Technology;Guangdong Provincial Key Laboratory of Silviculture,Protection and Utilization,Guangdong Academy of Forestry).Genomic, transcriptomic, and epigenomic analysis of a medicinal snake, Bungarus multicinctus, to provides insights into the origin of Elapidae neurotoxins[J].Acta Pharmaceutica Sinica B,2023,第5期
  • Hongjuan Zhang1,Ying Chen1,Yu Zhang1,Luyao Qiao1,Xiangyin Chi1,Yanxing Han1,Yuan Lin1,Shuyi Si2,Jiandong Jiang1,2(State Key Laboratory of Bioactive Substance and Function of Natural Medicines,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College;Institute of Medicinal Biotechnology,Chinese Academy of Medical Sciences and Peking Union Medical College).Identification of anti-Mycobacterium tuberculosis agents targeting the interaction of bacterial division proteins FtsZ and SepFe[J].Acta Pharmaceutica Sinica B,2023,第5期
  • Kan Xing Wu1,Thinesshwary Yogarajah2,3,Marcus Wing Choy Loe2,Parveen Kaur2,Regina Ching Hua Lee2,Chee Keng Mok4,Yi Hao Wong4,Patchara Phuektes5,Li Sze Yeo2,Vincent T.K.Chow2,3,Yong Wah Tan6,Justin Jang Hann Chu2,5,6,4(Lee Kong Chian School of Medicine,Nanyang Technological University;Department of Microbiology and Immunology,Yong Loo Lin School of Medicine,National University Health System,National University of Singapore;Infectious Disease Programme,Yong Loo Lin School of Medicine,National University of Singapore;NUSMed Biosafety Level 3 Core Facility,Yong Loo Lin School of Medicine,National University of Singapore;Department of Pathobiology,Faculty of Veterinary Medicine,Khonkaen University;Institute of Molecular and Cell Biology,Agency for Science,Technology and Research(A~*STAR)).The host-targeting compound peruvoside has a broad-spectrum antiviral activity against positive-sense RNA viruses[J].Acta Pharmaceutica Sinica B,2023,第5期
  • Binghe Xu1,Qingyuan Zhang2,Xichun Hu3,Qing Li1,Tao Sun4,Wei Li5,Quchang Ouyang6,Jingfen Wang7,Zhongsheng Tong8,Min Yan9,Huiping Li10,Xiaohua Zeng11,Changping Shan12,Xian Wang13,Xi Yan14,Jian Zhang3,Yue Zhang2,Jiani Wang1,Liang Zhang4,Ying Lin15,Jifeng Feng16,Qianjun Chen17,Jian Huang18,Lu Zhang19,Lisong Yang19,Ying Tian19,Hongyan Shang19(Department of Medical Oncology and State Key Laboratory of Molecular Oncology,National Cancer Cener/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College;Department of Medical Oncology,Harbin Medical University Cancer Hospital;Department of Medical Oncology,Fudan University Shanghai Cancer Center;Department of Galactophore,Liaoning Cancer Hospital & Institute;Department of Oncology,the First Hospital of Jilin University;Department of Galactophore,Hunan Cancer Hospital;Department of Galactophore,Linyi Cancer Hospital;Department of Breast Medical Oncology,Tianjin Medical University Cancer Institute & Hospital;Department of Breast Disease,Henan Breast Cancer Center,the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital;Department of Breast Oncology,Beijing Cancer Hospital;Breast Cancer Center,Chongqing University Cancer Hospital;Department of Breast and Thyroid Oncology,Affiliated Hospital of Jining Medical University;Department of Medical Oncology,Run Run Shaw Hospital,Affiliated Hospital of Zhejiang University;Department of Head and Heck Oncology,West China Hospital,Sichuan University;Department of Thyroid & Breast Surgery,the First Affiliated Hospital of Sun Yat-sen University;Department of Medical Oncology,Jiangsu Cancer Hospital;Department of Galactophore,Guangdong Hospital of Traditional Chinese Medicine;Department of Oncological Surgery,the Second Affiliated Hospital,Zhejiang University School of Medicine;Taizhou EOC Pharma Co.Ltd.).Entinostat, a class Ⅰ selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer:A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial[J].Acta Pharmaceutica Sinica B,2023,第5期
  • Damijan Knez1,Daniel Diez-Iriepa2,3,Mourad Chioua2,3,Andrea Gottinger4,Milica Denic5,Fabien Chantegreil5,Florian Nachon5,Xavier Brazzolotto5,Anna Skrzypczak-Wiercioch6,An?e Meden1,Anja Pi?lar1,Janko Kos1,Simon ?akelj1,Jure Stojan7,Kinga Sa?at8,Julia Serrano9,Ana Patricia Fernández9,Aitana Sánchez-García10,Ricardo Martínez-Murillo9,Claudia Binda4,Francisco López-Mu?oz11,Stanislav Gobec1,José Marco-Contelles2(University of Ljubljana,Faculty of Pharmacy;Laboratory of Medicinal Chemistry(Institute of Organic Chemistry,CSIC);Departamento de Química Orgánicay Química Inorgánica;Department of Biology and Biotechnology,University of Pavia;Département de Toxicologie et Risques Chimiques,Institut de Recherche Biomédicale des Armées;Department of Animal Anatomy and Preclinical Sciences,University Centre of Veterinary Medicine JU-UA,University of Agriculture in Krakow;Institute of Biochemistry,Faculty of Medicine,University of Ljubljana;Department of Pharmacodynamics,Chair of Pharmacodynamics,Faculty of Pharmacy,Jagiellonian University Medical College;Department of Translational Neurobiology,Neurovascular Research Group,Cajal Institute(CSIC);Biotechnology and Vegetal Biology Department,Escuela Técnica Superior de Ingeniería Agronómica,Alimentaria y de Biosistemas,Universidad Politécnica de Madrid;Faculty of Health,Camilo José Cela University of Madrid(UCJC),Neuropsychopharmacology Unit,"Hospital 12 de Octubre" Research Institute).8-Hydroxyquinolylnitrones as multifunctional ligands for the therapy of neurodegenerative diseases[J].Acta Pharmaceutica Sinica B,2023,第5期
  • Lijuan Ma1,Jing Zhang1,Ling Lin1,Tuanjie Wang2,Chaofu Ma1,Xiaomeng Wang1,Mingshuang Li1,Yanjiang Qiao1,Yongxiang Wang3,Guimin Zhang4,Zhisheng Wu1(Beijing University of Chinese Medicine,Engineering Research Center for Pharmaceutics of Chinese Materia Medica and New Drug Development,Ministry of Education;Jiangsu Kanion Pharmaceutical Co.Ltd.,State Key Laboratory of New Technology in Pharmaceutical Process of Traditional Chinese Medicine;Yangtze River Pharmaceutical (Group) Co.Ltd.,State Pharmaceutical Engineering Technology Research Center of Traditional Chinese Medicine;Lunan Pharmaceutical Group Co.Ltd.,State Key Laboratory of Generic Technology of Traditional Chinese Medicine).Data-driven engineering framework with AI algorithm of Ginkgo Folium tablets manufacturing[J].Acta Pharmaceutica Sinica B,2023,第5期
首页 上一页 5 6 7 8 9 下一页 尾页 共有12页,转到 页

帮助 | 繁體中文 | 关于发现 | 联系我们

超星发现系统 Copyright©·powered by 超星

客服电话:4008236966